Compare IDEXX Laboratories, Inc. (IDXX) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Sea Limited — how do they compare? IDEXX Laboratories, Inc. trades at $519.93 (market cap $40.43B), while Sea Limited trades at $95.21 (market cap $56.89B). The key difference: Sea Limited is the larger of the two by market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 5,359,457). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Sea Limited for 102 Days on average.
| IDXX | SE | |
|---|---|---|
Market Cap | $40.43B | $56.89B |
Volume | 692,164 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $188.00 |
52-Week Low | $504.70 | $78.16 |
Typical Hold Time | 46 Days | 102 Days |
Enterprise Value | $41.32B | $51.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Sea Limited (SE) trades at $95.40, up 0.78% with bearish technical signals but strong fundamentals. The company shows impressive revenue growth from $12.4B in 2022 to $22.9B in 2025, achieving profitability with net income of $1.58B. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus remains strongly bullish with a $153.67 price target representing 61% upside potential.
SE presents a compelling growth story with expanding profitability and positive cash flow generation. Key risks include competitive pressures in e-commerce and gaming markets, while the technical bearish signal and recent insider selling warrant monitoring. The significant gap between current price and analyst targets suggests potential for substantial upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
